In-transit melanoma advance is difficult to predict

In-transit melanoma advance is difficult to predict
Progressive disease cannot be reliably predicted by patient, clinical, or procedural factors in patients receiving regional therapy for advanced melanoma of the extremities, according to a study published online April 3 in JAMA Surgery.

(HealthDay)—Progressive disease cannot be reliably predicted by patient, clinical, or procedural factors in patients receiving regional therapy for advanced melanoma of the extremities, according to a study published online April 3 in JAMA Surgery.

Michael E. Lidsky, M.D., and colleagues from Duke University Medical Center in Durham, N.C. analyzed data from 215 in-transit patients who had undergone first-time regional therapy by either -based isolated limb infusion (ILI, 134 patients) or melphalan-based hyperthermic isolated limb perfusion (HILP, 81 patients).

The researchers found that in the ILI group, 32.1 percent had and 29.9 percent had a complete response. In the HILP group, 11.1 percent had progressive disease and 44.4 percent had a complete response. For patients with in-field progressive disease, median survival was 20.3 months for the ILI group and 15.0 months for the HILP group. Younger patients were at greater risk of progressive disease in the ILI group (odds ratio, 1.06) while no clinically relevant preoperative factors were identified predicting progressive disease in the HILP group. Procedural variables were not predictors of in-field progressive disease after ILI or HILP.

"Patient, clinical, and procedural factors are unreliable predictors of in-field progressive disease after regional therapy in patients with in-transit melanoma," Lidsky and colleagues conclude.

One author reported with drug companies.

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Pancreatectomy OK without downstaging from therapy

date May 25, 2012

(HealthDay) -- Pancreatectomy improves median survival in pancreatic cancer patients even when presurgical neoadjuvant therapy does not lead to radiographic downstaging of tumors, according to a study published ...

Exercise stimulates adiponectin, raises HDL levels

date Oct 18, 2012

(HealthDay)—Intensive lifestyle intervention for weight loss (ILI) significantly improves high-density lipoprotein cholesterol (HDL-C) levels in overweight and obese individuals with type 2 diabetes, which ...

Lexatumumab tolerated for pediatric solid tumors

date Oct 16, 2012

(HealthDay)—Lexatumumab, an agonistic, full human monoclonal antibody against tumor necrosis factor-related apoptosis-inducing ligand receptor 2, is well tolerated and may lessen certain clinical symptoms ...

Recommended for you

Spanish hospital conducts complex face transplant

date Mar 30, 2015

A Spanish hospital said Monday it has successfully carried out the world's most complex face transplant, reconstructing the lower face, neck, mouth, tongue and back of the throat of a man terribly disfigured by disease.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.